Abstract: The present disclosure describes new meat products and new processing and cutting techniques that more effectively utilize an animal carcass. A boneless rib-meat product and method of producing the same are disclosed. The boneless meat product includes two boneless rib-meat portions, each boneless rib-meat portion has an interior side. The interior side includes alternating raised surfaces and depressions. The two boneless rib-meat portions are positioned together in a stacked configuration with the interior side of each boneless rib-meat portion oriented toward and in contact with the other. The raised surfaces of each boneless rib-meat portion are offset with each other such that the raised surfaces of each boneless rib-meat portion are positioned within a corresponding depression of the other boneless rib-meat portion. The stacked boneless rib-meat portions are secured together via cooking to cause the boneless rib-meat portions to bind together.

Abstract: The present disclosure describes new meat products and new processing and cutting techniques that more effectively utilize the animal carcass. A method of forming a rib-meat product and one or more rib-meat products are disclosed. One rib-meat product includes a plurality of rib bones and a substantially cylindrically-shaped meat portion attached to a second end of each of the rib bones in the plurality of rib bones. The substantially cylindrically-shaped meat portion is a continuous piece of meat originally present on the plurality of rib bones. The substantially cylindrically-shaped meat portion includes a flap portion and a stationary portion, and the flap portion has been detached from each of the first ends of the plurality of rib bones and is substantially wrapped around a stationary portion at the second end to form the substantially cylindrically-shaped meat portion.

Abstract: Systems and methods enabling the automatic configuration of application environments in a clinical system are disclosed. An interoperability hub can be implemented within a clinical solution made up of a plurality of independent application environments. Each application environment may have an interoperability agent running on it which facilitates communication with the interoperability hub. Each agent running on a specific application environment is configured to look into that system and collect configuration information from that application environment that other systems in the solution require. The configuration information for an application environment can be sent to the interoperability hub and maintained. Further, if that application environment requires any configuration information from any other application environment, it can obtain that information from the interoperability hub and handle that information appropriately with respect to the application environment.

Abstract: Systems and methods enabling the automatic configuration of application environments in a clinical system are disclosed. An interoperability hub can be implemented within a clinical solution made up of a plurality of independent application environments. Each application environment may have an interoperability agent running on it which facilitates communication with the interoperability hub. Each agent running on a specific application environment is configured to look into that system and collect configuration information from that application environment that other systems in the solution require. The configuration information for an application environment can be sent to the interoperability hub and maintained. Further, if that application environment requires any configuration information from any other application environment, it can obtain that information from the interoperability hub and handle that information appropriately with respect to the application environment.

Abstract: The present disclosure describes new meat products and new processing and cutting techniques that more effectively utilize an animal carcass. A method of forming one or more bone-in products and one or more boneless meat products from the same segment of carcass are disclosed. The bone-in meat products and boneless meat products are formed by dividing a carcass segment having at least three rib bones into a bone-in meat portion and a boneless meat portion. The bone-in meat portion has a portion of rib bones exposed and a generally cylindrically meat member spanning its length. The boneless meat portion may be a formed by enveloping the meat portion with a flap created from attached fat or skin of the boneless meat portion thereby forming a boneless meat product that is a continuous piece of material and generally cylindrical in shape.

Abstract: A method of cutting a pork loin creating an anterior portion, a center portion, and posterior portion of a pork loin to provide pork products having enhanced value. The method includes cutting an anterior portion of a pork loin to form a first portion and a second portion, the first portion including a substantially intact spinalis dorsi and multifidus muscles, and a substantially intact longissimus dorsi in the second portion. The method also includes cutting a posterior portion of a pork loin in a manner that results in a substantially intact gluteus medius muscle such that the resulting pork product resembles a pork loin filet in appearance and shape.

Abstract: A method of cutting a pork loin creating an anterior portion, a center portion, and posterior portion of a pork loin to provide pork products having enhanced value. The method includes cutting an anterior portion of a pork loin to form a first portion and a second portion, the first portion including a substantially intact spinalis dorsi and multifidus muscles, and a substantially intact longissimus dorsi in the second portion. The method also includes cutting a posterior portion of a pork loin in a manner that results in a substantially intact gluteus medius muscle such that the resulting pork product resembles a pork loin filet in appearance and shape.

Abstract: Selective MMP-13 inhibitors are isophthalic acid derivatives of the formula wherein: R1, R2, and R3 independently are hydrogen, halo, hydroxy, C1–C6 alkyl, C1–C6 alkoxy, C2–C6 alkenyl, C2–C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; each R4 and R5 independently are H, C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6; or a pharmaceutically acceptable salt thereof. The compounds are useful for treating diseases in a mammal that are mediated by MMP enzymes.

Abstract: Disclosed is a system including a circuit board and several pluggable modules coupled to the circuit board. The several pluggable modules are insertable through side-by-side slots in an enclosure in which the circuit board resides. A first pluggable module is coupled to the circuit board via a first connector, while a second pluggable module is coupled to the circuit board via a second connector such that the second pluggable module is laterally offset from the first pluggable module. The first and second connectors are right angle connectors, and the second right angle connector is inverted relative to the first right angle connector. The first and second pluggable modules are I/O modules for transporting high speed differential signals, and wherein the first pluggable module includes several XFP connectors, and wherein the second pluggable module includes several SFP connectors. The second pluggable module includes several SFP connectors arranged on both sides of the pluggable module.

Abstract: Selective MMP-13 inhibitors are pyridine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are hydrogen, halo, hydroxy, C1–C6 alkyl, C1–C6 alkoxy, C2–C6 alkenyl, C2–C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; R4 and R5 independently are H, C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is an integer of from 0 to 6.

Abstract: Selective MMP-13 inhibitors are isophthalic acid derivatives of the formula wherein: R1, R2, and R3 independently are hydrogen, halo, hydroxy, C1–C6 alkyl, C1–C6 alkoxy, C2–C6 alkenyl, C2–C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; each R4 and R5 independently are H, C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6; or a pharmaceutically acceptable salt thereof. The compounds are useful for treating diseases in a mammal that are mediated by MMP enzymes.

Abstract: A multi-display computer system comprises a display member rotatably coupled to a base member. The display member has a first display device disposed on an interior surface thereof and a second display device disposed on an exterior surface thereof. The computer system also comprises a display manager executable by a processor and adapted to enable a user to automatically control a display mode of the second display device independent of a display mode of the first display device.

Abstract: Disclosed is a system including a circuit board and several pluggable modules coupled to the circuit board. The several pluggable modules are insertable through side-by-side slots in an enclosure in which the circuit board resides. A first pluggable module is coupled to the circuit board via a first connector, while a second pluggable module is coupled to the circuit board via a second connector such that the second pluggable module is laterally offset from the first pluggable module. The first and second connectors are right angle connectors, and the second right angle connector is inverted relative to the first right angle connector. The first and second pluggable modules are I/O modules for transporting high speed differential signals, and wherein the first pluggable module includes several XFP connectors, and wherein the second pluggable module includes several SFP connectors. The second pluggable module includes several SFP connectors arranged on both sides of the pluggable module.

Abstract: Selective MMP-13 inhibitors are pyridine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3, E is independently O or S; A and B independently are OR4 or NR4R5; R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted, n is an integer of from 0 to 6.

Abstract: Disclosed are systems and methods for de-skewing media when using an automatic media feeder comprising a registration guide and a registration tab disposed to cooperate with the registration guide in providing de-skewing of media when an edge of the media passes over the registration tab and is deflected thereby toward the registration guide.

Abstract: This invention provides indole and benzimidazole 15-lipoxygenase (15-LO) inhibitors of the formula where one of Y1 and Y2 is CH, N, or NH, and the other is R3 includes H, halo, HN2, COOH, alkyl; R4 includes halo, alkyl, and alkoxy; Z is C, CH, or NR5; R5 is H or oxycabonyl; and each X is independently H, alkyl, alkoxy, or halo.

Abstract: Selective MMP-13 inhibitors are pyridine derivatives of the formula 1

Abstract: This invention provides indole and benzimidazole 15-lipoxygenase (15-LO) inhibitors of the formula where one of Y1 and Y2 is CH, N, or NH, and the other is R3 includes H, halo. HN2, COOH, alkyl; R4 includes halo, alkyl, and alkoxy; Z is C, CH, or NR5; R5 is H or oxycabonyl; and each X is independently H, alkyl, alkoxy, or halo.

Abstract: Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.

Abstract: The present invention relates to novel compounds and medical methods of treatment of inflammation, atherosclerosis, restenosis, and immune disorders especially those associated with lymphocyte or monocyte accumulation such as arthritis and transplant rejection. More particularly, the present invention concerns the use of 2-phenyl benzimidazole derivatives.